샘플 요청 목록

 카트 문의
시장보고서
상품코드
1437516

세계 히드록시딘 시장 : 제형별, 적응증별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Hydroxyzine Market, By Dosage Form, By Indication Type, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 289 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

히드록시딘 시장 규모는 2023년에 2억 1,330만 달러로 평가되었고 2024년부터 2032년까지 복합 연간 성장률(CAGR) 5.5%로 확대될 전망입니다

히드록시딘 시장 : 시장 역학

알레르기 유병률 상승이 시장 성장을 견인

지난 수십년동안 세계 알레르기와 관련 질환의 빈도가 증가하고 있습니다. 알레르기 반응을 경험하는 사람의 수는 여러 가지 이유로 증가하고 있습니다. 그 예로, 2022년 4월에 마지막으로 업데이트된 Allergy Facts and Figures에 따르면, 미국에서는 알레르기가 만성 질환의 6번째로 많은 원인이 되고 있으며, 매년 약 5,000만 명이 병을 앓고 있습니다. 그 결과 미국에서는 알레르기의 유병률이 높아 치료법의 개선이 필요합니다. 이와 관련하여 2021년 11월 IJERPH에 발표된 논문에서 알레르기의 정확한 원인은 불분명하지만 유전적 및 환경적 요인이 알레르기 질환의 세계적 부담에 크게 기여하고 있습니다. 라고 합니다. 또한, 일부 연구에 따르면, 히드록시딘은 알레르기와 관련된 가려움증을 완화시키는 데 이용될 수 있습니다. 히드록시딘은 항히스타민제이며 알레르기 반응이 일어날 때 히스타민으로 알려진 특정 유기 화합물이 신체에서 생산되는 것을 방지함으로써 작용합니다. 따라서 질병 부담을 조절하기 위해 히드록시딘의 필요성이 증가하고 있습니다. 그 결과, 대상 인구의 알레르기 부하가 크고, 알레르기에 대한 히드록시딘의 치료상의 이점이 시장 확대의 원동력이 될 것으로 예상됩니다.

히드록시딘 시장 : 주요 인사이트력

우리의 리서치 애널리스트가 공유한 분석에 따르면 시장은 예측 기간(2024-2032년)에 약 5.5%의 복합 연간 성장률(CAGR)로 매년 성장할 것으로 예측됩니다.

제형 세분화에서는 정제가 시장을 독점하고 있으며 예측 기간 동안에도 우위를 유지할 가능성이 높습니다.

Based on indication type segmentation, the atopic contact dermatitis segment is expected to hold the largest market share during the forecast period

지역별로는 북미가 2023년 매출에서 최고

히드록시딘 시장 : 세분화 분석

시장 세분화

시장은 복용 형태에 따라 캡슐, 정제, 주사제, 시럽의 네 가지 범주로 분류됩니다. 태블릿 부문은 시장을 지배하고 있으며 예측 기간 동안에도 우위를 유지할 수 있습니다. 히드록시딘과 같은 항히스타민제는 소화기계에서 신속하게 흡수되며 경구 투여 후 15-30분 후에 임상 효과가 나타나기 시작합니다. 이들은 정신,신경질환에 의해 초래되는 스트레스나 불안을 경감하는 것을 목적으로 하고 있습니다. 수술 전 수면을 촉진합니다. 이 카테고리는 알레르기성 질환과 불안증의 치료에 정제의 제형이 사용되고 신경질환의 유병률 증가에 의해 확대되고 있습니다.

국제 습진 협의회(International Eczema Council 2022)에 따르면 아토피 피부염은 매우 만연하며 성인의 최대 10%, 어린이의 최대 20%가 영향을 받고 있습니다. 게다가 질병 부담은 장애조정 생존연수로 평가되는 피부질환에서는 세계 제1위, 비치사적 질환에서는 세계 제15위가 되고 있습니다.

히드록시딘 시장 : 지리적 인사이트

히드록시딘 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카에 퍼져 있습니다. 이 지역은 비즈니스를 전개하는 국가에 따라 더 나뉩니다. 북미는 아토피성 접촉 피부염의 빈도가 높고, 확립된 인프라를 이용할 수 있는 것, 불안이나 신경장애의 치료에 대한 의식이 높아지고 있음, 수탁연구기관과 제약기업과의 협력관계가 증가하고 있는 것 등으로부터(2023년)에는 최대 시장 점유율을 차지할 것으로 예상되고, 예측 기간 중에도 같은 패턴이 계속될 것으로 보여지고 있습니다. CDC에 따르면 정신건강을 받는 사람의 비율은 2019년과 2021년 사이에 모든 연령의 성인에서 19.2%에서 21.6%로, 18세에서 44세까지 18.5%에서 23.2% 에 상승했습니다. 게다가 18세에서 44세 사이에서 남성보다 여성이 정신 건강 관리를 받을 가능성이 더 높았습니다.

히드록시딘 시장 : 경쟁 구도:

주요 시장 진출기업은 Alliance Pharma PLC, OAK PHARMS INC., Teva Pharmaceutical Industries, Piramal Healthcare UK Limited, Pfizer Inc., Shanghai Ruizheng Chemical Technology Co.Ltd., Lupin Pharmaceuticals, Inc. Changzhou ComWin Fine Chemicals Co.Ltd., Impax Laboratories, Inc., Novartis International AG입니다. 이러한 기업들은 시장 경쟁력을 유지하기 위해 제품 출시, 인수, 사업 확대, 승인, 계약 등 다양한 유형의 전략을 채택하고 있습니다.

목차

제1장 히드록시딘 시장 개요

  • 조사 범위
  • 시장 추정 연도

제2장 주요 요약

  • 시장 분석
  • 경쟁 인사이트

제3장 히드록시딘의 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 향후 시장 동향

제4장 히드록시딘 산업의 조사

  • PEST 분석
  • Porter's Five Forces 분석
  • 성장 전망 맵핑
  • 규제 틀의 분석

제5장 히드록시딘 시장 : COVID-19증의 영향 분석

  • 신형 코로나바이러스 감염증 이전의 영향 분석
  • 신형 코로나바이러스 감염증 후의 영향 분석

제6장 히드록시딘 시장 상황

  • 히드록시딘 시장 점유율 분석(2023년)
  • 주요 제조업체별 분석 데이터
    • 기존 기업의 분석
    • 신흥기업의 분석

제7장 히드록시딘 시장 : 제형별

  • 개요
    • 제형별 부문 점유율 분석
    • 캡슐
    • 태블릿
    • 주사
    • 시럽

제8장 히드록시딘 시장 : 적응증유형별

  • 개요
    • 적응증별 부문 점유율 분석
    • 두드러기
    • 히스타민 매개 소양증
    • 아토피성 접촉 피부염

제9장 히드록시딘 시장 : 지역별

  • 소개
  • 북미
    • 개요
    • 북미 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽 주요 제조업체
    • 독일
    • 이탈리아
    • 영국
    • 프랑스
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 개요
    • 아시아태평양 주요 제조업체
    • 인도
    • 중국
    • 일본
    • 한국
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 라틴아메리카
    • 개요
    • 라틴아메리카 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제10장 주요 벤더 분석 - 히드록시딘 업계

  • 경쟁 대시보드
  • 기업 프로파일
    • Alliance Pharma PLC
    • OAK PHARMS INC.
    • Teva Pharmaceutical Industries
    • Piramal Healthcare UK Limited
    • Pfizer Inc.
    • Shanghai Ruizheng Chemical Technology Co., Ltd
    • Lupin Pharmaceuticals, Inc.
    • GlaxoSmithKline plc
    • Changzhou ComWin Fine Chemicals Co., Ltd
    • Impax Laboratories, Inc.
    • Novartis International AG

제11장 애널리스트의 전방위 전망

BJH 24.03.08

REPORT HIGHLIGHT

Hydroxyzine Market size was valued at USD 213.30 Million in 2023, expanding at a CAGR of 5.5% from 2024 to 2032.

Hydroxyzine is an N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy) ethyl and (4-chlorophenyl) (phenyl)methyl groups respectively. It has a role as a H1-receptor antagonist, an anxiolytic drug, a dermatologic drug, an antipruritic drug and an anticoronaviral agent. It is an N-alkylpiperazine, a hydroxyether and a member of monochlorobenzenes.

Hydroxyzine Market- Market Dynamics

The rising prevalence of allergies drives market growth

Over the past several decades, there has been an increase in the frequency of allergies and associated disorders worldwide. The number of people experiencing allergic reactions is increasing for several reasons. As an illustration, Allergy Facts and Figures, which was last updated in April 2022, states that allergies account for the sixth most common cause of chronic disease in the United States, affecting almost 50 million individuals annually. As a result, the nation has a high prevalence of allergies, necessitating improved treatment alternatives. In this regard, a paper published in November 2021 in IJERPH states that, even though the exact causes of allergies are unclear, hereditary and environmental factors contribute significantly to the global burden of allergic illnesses. Furthermore, hydroxyzine may be utilized to relieve allergy-related itching, according to several studies. It is an antihistamine that functions by preventing the body from producing particular organic compounds known as histamine when an allergic response occurs. Thus, there is a growing need for hydroxyzine to control the burden of illness. As a result, the target population's significant allergy load and hydroxyzine therapeutic advantages for allergies are anticipated to drive market expansion.

Hydroxyzine Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.5% over the forecast period (2024-2032)

Based on dosage form segmentation, the tablets segment dominates the market and is likely to maintain its dominance during the forecast period

Based on indication type segmentation, the atopic contact dermatitis segment is expected to hold the largest market share during the forecast period

Based on region, North America was the leading revenue generator in 2023

Hydroxyzine Market- Segmentation Analysis:

The Global Hydroxyzine Market is segmented based on Dosage form, Indication type and Region.

The market is divided into four categories based on dosage form: capsules, tablets, injections, and syrup. The tablet segment dominates the market and is likely to maintain its dominance during the forecast period. Antihistamine medications such as hydroxyzine are quickly absorbed from the digestive system and start to show clinical effects 15 to 30 minutes after oral administration. These are intended to reduce stress and anxiety brought on by mental and neurological disorders. It facilitates sleep before surgery. The category is growing due to the increasing use of tablet dosage forms for the treatment of allergic illnesses and anxiety, as well as an increase in the prevalence of neurological disorders.

The market is divided into three categories based on indication type: urticaria, histamine-mediated pruritus and atopic contact dermatitis. The atopic contact dermatitis segment is expected to hold the largest market share during the forecast period. The market's revenue has increased as a result of the growing demand for hydroxyzine dosage forms and the increasing prevalence of atopic dermatitis. As per the International Eczema Council 2022, atopic dermatitis is highly prevalent, impacting up to 10% of adults and 20% of children. Furthermore, the illness burden is ranked first for skin conditions evaluated in disability-adjusted life years and 15th globally for nonfatal disorders.

Hydroxyzine Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to hold a maximum market share in 2023 and is expected to continue the same pattern during the forecast period due to the high frequency of atopic contact dermatitis, the availability of well-established infrastructure, the rising awareness of anxiety and nervous disorder therapies, and the rise in collaborations between contract research organizations and pharmaceutical corporations. According to the CDC, the proportion of people receiving mental health care went up from 19.2% to 21.6% for adults of all ages and from 18.5% to 23.2% for individuals between the ages of 18 and 44 between 2019 and 2021. Furthermore, women were more likely than males to undergo mental health care among people aged 18 to 44.

Hydroxyzine Market- Competitive Landscape:

The key players operating in the market are Alliance Pharma PLC, OAK PHARMS INC., Teva Pharmaceutical Industries, Piramal Healthcare UK Limited, Pfizer Inc., Shanghai Ruizheng Chemical Technology Co., Ltd, Lupin Pharmaceuticals, Inc., GlaxoSmithKline plc, Changzhou ComWin Fine Chemicals Co., Ltd, Impax Laboratories, Inc. and Novartis International AG. These players adopted various types of strategies to remain competitive in the market such as product launches, acquisitions, expansion, approvals, agreements and others.

Recent Developments:

In December 2022, the HPRA approved Brillpharma (Ireland) to commercialize Hydroxyzine hydrochloride 25 mg film-coated tablets. These have adult anxiety management licenses.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HYDROXYZINE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Alliance Pharma PLC

OAK PHARMS INC.

Teva Pharmaceutical Industries

Piramal Healthcare UK Limited

Pfizer Inc.

Shanghai Ruizheng Chemical Technology Co., Ltd

Lupin Pharmaceuticals, Inc.

GlaxoSmithKline plc

Changzhou ComWin Fine Chemicals Co., Ltd

Impax Laboratories, Inc.

Novartis International AG

GLOBAL HYDROXYZINE MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

  • Capsules
  • Tablets
  • Injections
  • Syrup

GLOBAL HYDROXYZINE MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Urticaria
  • Histamine-Mediated Pruritus
  • Atopic Contact Dermatitis

GLOBAL HYDROXYZINE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Hydroxyzine Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Hydroxyzine Market Snippet by Dosage Form
    • 2.1.2. Hydroxyzine Market Snippet by Indication Type
    • 2.1.3. Hydroxyzine Market Snippet by Country
    • 2.1.4. Hydroxyzine Market Snippet by Region
  • 2.2. Competitive Insights

3. Hydroxyzine Key Market Trends

  • 3.1. Hydroxyzine Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Hydroxyzine Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Hydroxyzine Market Opportunities
  • 3.4. Hydroxyzine Market Future Trends

4. Hydroxyzine Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Hydroxyzine Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Hydroxyzine Market Landscape

  • 6.1. Hydroxyzine Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Hydroxyzine Market - By Dosage Form

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Dosage Form, 2023 & 2032 (%)
    • 7.1.2. Capsules
    • 7.1.3. Tablets
    • 7.1.4. Injections
    • 7.1.5. Syrup

8. Hydroxyzine Market - By Indication Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication Type, 2023 & 2032 (%)
    • 8.1.2. Urticaria
    • 8.1.3. Histamine-Mediated Pruritus
    • 8.1.4. Atopic Contact Dermatitis

9. Hydroxyzine Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Hydroxyzine Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Hydroxyzine Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Hydroxyzine Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Hydroxyzine Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Hydroxyzine Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Hydroxyzine Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Alliance Pharma PLC
    • 10.2.2. OAK PHARMS INC.
    • 10.2.3. Teva Pharmaceutical Industries
    • 10.2.4. Piramal Healthcare UK Limited
    • 10.2.5. Pfizer Inc.
    • 10.2.6. Shanghai Ruizheng Chemical Technology Co., Ltd
    • 10.2.7. Lupin Pharmaceuticals, Inc.
    • 10.2.8. GlaxoSmithKline plc
    • 10.2.9. Changzhou ComWin Fine Chemicals Co., Ltd
    • 10.2.10. Impax Laboratories, Inc.
    • 10.2.11. Novartis International AG

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제